You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

311 Results
Guidelines and Advice
Status: Archived
ID: 17-8
Jan 2014
Guidelines and Advice
Status: Archived
ID: 2-25
Dec 2013
Guidelines and Advice
Status: In-Review
ID: 2-4
Version: 3
Mar 2019
Guidelines and Advice
Status: Archived
ID: 11-8
Version: 2
Oct 2015
Guidelines and Advice
Status: Current
ID: 24-1
Version: 2
Apr 2017
Guidelines and Advice
Status: Archived
ID: MOAC 3
Sep 2015
Drug
Other Name(s): Stivarga®
Quick Link(s): Drug Monograph, Patient Info Sheet
Nov 2023
Guidelines and Advice
Status: In-Review
ID: 15-5
Version: 2
Sep 2013
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    everolimus - For patients who have progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumors (PNET), with specific criteria
Exceptional Access Program
    everolimus - Treatment of unresectable, locally advanced or metastatic, well-differentiated non-functional neuroendocrine tumours (NETs) of GI or lung origin, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
everolimus
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2024
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Durvalumab - Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
New Drug Funding Program
    Durvalumab in combination with Tremelimumab - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
durvalumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2024
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
nivolumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2024
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
nivolumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025

Pages